AIVITA Biomedical develops personalized vaccines using a pan-antigenic approach that targets all neoantigens to effectively address cancer's mutation challenges. Their autologous cell therapy platform also produces a multi-pathogen vaccine kit, providing adaptive immunity against a range of infectious diseases.
Funding
$70.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cancer's ability to mutate poses a significant challenge to traditional vaccine approaches that target only a select few neoantigens. This limitation can lead to treatment resistance and disease recurrence. Additionally, developing broad-spectrum vaccines against multiple pathogens is difficult due to the variability and evolution of infectious agents.
Solution
AIVITA Biomedical is developing personalized vaccines that target all neoantigens present in a patient's cancer cells, aiming to overcome the mutation challenges inherent in cancer treatment. Their autologous cell therapy platform is also used to create a multi-pathogen vaccine kit designed to provide adaptive immunity against a range of infectious diseases. This approach leverages the body's own cells to generate a targeted immune response, potentially offering a more effective and durable solution for both cancer and infectious disease prevention.
Target Audience
The primary target audience includes cancer patients seeking personalized treatment options and individuals at risk of infectious diseases looking for broad-spectrum preventative measures.
Features
- Pan-antigenic approach targeting all neoantigens to address cancer mutations
- Autologous cell therapy platform utilizing patient's own cells
- Personalized multi-pathogen vaccine kit for adaptive immunity
- Therapeutic vaccine programs with demonstrated safety and efficacy in early clinical trials
- Stem cell growth and differentiation technologies for efficient manufacturing